Werewolf Therapeutics (HOWL) Common Equity (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Common Equity of $16.3 million for Q2 2026, down 60.71% year-over-year from $41.5 million in Q2 2025, and up 33.52% on a QoQ basis from $12.2 million in Q1 2026.
Werewolf Therapeutics (HOWL) Common Equity (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Common Equity for 7 years, with the latest figure at $16.3 million in Q2 2026.
- Common Equity for Q2 2026 came in at $16.3 million, down 60.71% year-over-year; the trailing twelve-month figure through Jun 2026 was $16.3 million (down 60.71% YoY), and the FY2025 annual result was $24.8 million, down 66.2% from the prior year.
- Common Equity rose to $16.3 million in Q2 2026, from $12.2 million in the prior quarter.
- Over five years, Common Equity peaked at $139.3 million in Q1 2022 and troughed at $12.2 million in Q1 2026.
- A 5-year average of $86.2 million and a median of $107.7 million in 2023 frame the typical range for Common Equity.
- The widest annual swing landed in 2022, when Common Equity surged 190.61%; it then plunged 78.71% in 2026.
- A 5-year view of Common Equity shows it stood at $122.3 million in 2022, then dropped by 8.96% to $111.4 million in 2023, then sank by 34.1% to $73.4 million in 2024, then slumped by 66.2% to $24.8 million in 2025, then slumped by 34.32% to $16.3 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $16.3 million in Q2 2026, $12.2 million in Q1 2026, and $24.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 16.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.29 Mn |
| Mar 31, 2026 | 12.20 Mn |
| Dec 31, 2025 | 24.81 Mn |
| Sep 30, 2025 | 29.61 Mn |
| Jun 30, 2025 | 41.46 Mn |
| Mar 31, 2025 | 57.31 Mn |
| Dec 31, 2024 | 73.39 Mn |
| Sep 30, 2024 | 89.38 Mn |
| Jun 30, 2024 | 104.02 Mn |
| Mar 31, 2024 | 117.59 Mn |
| Dec 31, 2023 | 111.37 Mn |
| Sep 30, 2023 | 112.44 Mn |
| Jun 30, 2023 | 118.60 Mn |
| Mar 31, 2023 | 121.07 Mn |
| Dec 31, 2022 | 122.34 Mn |
| Sep 30, 2022 | 130.95 Mn |
| Jun 30, 2022 | 129.84 Mn |
| Mar 31, 2022 | 139.32 Mn |
| Dec 31, 2021 | 152.79 Mn |
| Sep 30, 2021 | 169.30 Mn |